Following this transaction, Schundler holds 487,328 shares of Liquidia common stock directly. Additionally, Schundler's indirect holdings include 14,500 shares held by his spouse, though he disclaims beneficial ownership of these securities except to the extent of his pecuniary interest. For deeper insights into Liquidia's financial health, valuation metrics, and comprehensive analysis, investors can access the detailed Pro Research Report available on InvestingPro, which offers exclusive data points and expert analysis for over 1,400 US stocks. For deeper insights into Liquidia's financial health, valuation metrics, and comprehensive analysis, investors can access the detailed Pro Research Report available on InvestingPro, which offers exclusive data points and expert analysis for over 1,400 US stocks.
Following this transaction, Schundler holds 487,328 shares of Liquidia common stock directly. Additionally, Schundler's indirect holdings include 14,500 shares held by his spouse, though he disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
In other recent news, Liquidia Corporation reported a rise in Q3 revenue to $4.4 million, an increase from the previous year's $3.7 million. However, the company also reported a net loss of $23.2 million. Despite this, Liquidia maintains a strong cash position with $204.4 million in reserves. The company is making strides towards the anticipated launch of its inhaled treatment YUTREPIA for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, expected post May 2025.
Liquidia is also preparing for a pivotal study of their product L606, with the study expected to start in the first half of 2025. The company has expanded its partnership with Pharmosa for the development of a next-generation nebulizer. This recent development highlights the company's ongoing commitment to innovative treatments for patients with pulmonary hypertension. The sales force is prepared to target the PH and PH-ILD markets, aiming to raise awareness and facilitate diagnoses. These are the recent developments in Liquidia Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.